Companion Home Health | |
1310 E Oklahoma Avenue, Guthrie, Oklahoma 73044 | |
(405) 293-9000 | |
Name | Companion Home Health |
---|---|
Location | 1310 E Oklahoma Avenue, Guthrie, Oklahoma |
Certified By | Medicare |
Services Offered | Nursing Care Physical Therapy Occupational Therapy Speech Pathology Medical Social Services Home Health Aide |
Medicare ID | 377683 |
Ownership Type | Proprietary |
Service Area Zip Codes | 73003, 73007, 73012, 73013, 73016, 73025, 73027, 73028, 73034, 73044, 73050, 73054, 73056, 73058, 73063, 73073, 73077, 73101, 73103, 73112, 73114, 73116, 73120, 73130, 73132, 73134, 73142, 73151, 74059, 74074, 74075, 74881 |
NPI Number | 1245233170 |
Organization Name | COMPANION HOME HEALTH, LLC |
Address | 1310 E Oklahoma Ave, Guthrie, OK 73044 |
Phone Number | 405-282-3402 |
News Archive
A single compound with dual function - the ability to deliver a diagnostic and therapeutic agent - may one day be used to enhance the diagnosis, imaging and treatment of brain tumors, according to findings from Virginia Commonwealth University and Virginia Tech.
UCB has announced the submission of a Biologics License Application (BLA) to the United States Food and Drug Administration (FDA) for the approval of CIMZIA (certolizumab pegol, CDP870) for the treatment of patients with Crohn's disease.
Neurofeedback is a technique used for the treatment of clinical disorders (like depression, anxiety, chronic pain, ADHD and schizophrenia etc.) and enhancement of brain performance.
Tibotec Pharmaceuticals Ltd. has announced the submission of a New Drug Application to the U.S. Food and Drug Administration (FDA) for TMC125 (etravirine), an investigational non- nucleoside reverse transcriptase inhibitor (NNRTI), being studied for use with other antiretroviral (ARV) agents as a treatment for people infected with HIV- 1.
› Verified 8 days ago
NPI Number | 1821360769 |
Organization Name | COMPANION AT HOME, LLC |
Address | 1310 E Oklahoma Ave Ste B, Guthrie, OK 73044 |
Phone Number | 405-282-1307 |
News Archive
A single compound with dual function - the ability to deliver a diagnostic and therapeutic agent - may one day be used to enhance the diagnosis, imaging and treatment of brain tumors, according to findings from Virginia Commonwealth University and Virginia Tech.
UCB has announced the submission of a Biologics License Application (BLA) to the United States Food and Drug Administration (FDA) for the approval of CIMZIA (certolizumab pegol, CDP870) for the treatment of patients with Crohn's disease.
Neurofeedback is a technique used for the treatment of clinical disorders (like depression, anxiety, chronic pain, ADHD and schizophrenia etc.) and enhancement of brain performance.
Tibotec Pharmaceuticals Ltd. has announced the submission of a New Drug Application to the U.S. Food and Drug Administration (FDA) for TMC125 (etravirine), an investigational non- nucleoside reverse transcriptase inhibitor (NNRTI), being studied for use with other antiretroviral (ARV) agents as a treatment for people infected with HIV- 1.
› Verified 8 days ago
Quality Rating: |
News Archive
A single compound with dual function - the ability to deliver a diagnostic and therapeutic agent - may one day be used to enhance the diagnosis, imaging and treatment of brain tumors, according to findings from Virginia Commonwealth University and Virginia Tech.
UCB has announced the submission of a Biologics License Application (BLA) to the United States Food and Drug Administration (FDA) for the approval of CIMZIA (certolizumab pegol, CDP870) for the treatment of patients with Crohn's disease.
Neurofeedback is a technique used for the treatment of clinical disorders (like depression, anxiety, chronic pain, ADHD and schizophrenia etc.) and enhancement of brain performance.
Tibotec Pharmaceuticals Ltd. has announced the submission of a New Drug Application to the U.S. Food and Drug Administration (FDA) for TMC125 (etravirine), an investigational non- nucleoside reverse transcriptase inhibitor (NNRTI), being studied for use with other antiretroviral (ARV) agents as a treatment for people infected with HIV- 1.
› Verified 8 days ago
Quality Measure | Provider | National Avg. |
---|---|---|
How often the home health team began their patients’ care in a timely manner | 98.1 | 95.7 |
How often the home health team taught patients (or their family caregivers) about their drugs | 100 | 98.6 |
How often the home health team checked patients’ risk of falling | 99.7 | 99.6 |
How often the home health team checked patients for depression | 97.3 | 97.4 |
How often the home health team made sure that their patients have received a flu shot for the current flu season. | 89.4 | 78.7 |
How often the home health team made sure that their patients have received a pneumococcal vaccine (pneumonia shot). | 90.9 | 82.2 |
With diabetes, how often the home health team got doctor’s orders, gave foot care, and taught patients about foot care | 97.2 | 96.4 |
News Archive
A single compound with dual function - the ability to deliver a diagnostic and therapeutic agent - may one day be used to enhance the diagnosis, imaging and treatment of brain tumors, according to findings from Virginia Commonwealth University and Virginia Tech.
UCB has announced the submission of a Biologics License Application (BLA) to the United States Food and Drug Administration (FDA) for the approval of CIMZIA (certolizumab pegol, CDP870) for the treatment of patients with Crohn's disease.
Neurofeedback is a technique used for the treatment of clinical disorders (like depression, anxiety, chronic pain, ADHD and schizophrenia etc.) and enhancement of brain performance.
Tibotec Pharmaceuticals Ltd. has announced the submission of a New Drug Application to the U.S. Food and Drug Administration (FDA) for TMC125 (etravirine), an investigational non- nucleoside reverse transcriptase inhibitor (NNRTI), being studied for use with other antiretroviral (ARV) agents as a treatment for people infected with HIV- 1.
› Verified 8 days ago
Quality Measure | Provider | National Avg. |
---|---|---|
How often patients got better at walking or moving around | 78.4 | 79.6 |
How often patients got better at getting in and out of bed | 80.9 | 81.1 |
How often patients got better at bathing | 85.3 | 82.3 |
How often patients’ breathing improved | 87.8 | 82.8 |
How often patients’ wounds improved or healed after an operation | 95.4 | 92.3 |
How often patients got better at taking their drugs correctly by mouth | 82.5 | 75 |
How often home health patients had to be admitted to the hospital | 12.3 | 15.4 |
How often patients receiving home health care needed urgent, unplanned care in the ER without being admitted | 20.5 | 13 |
How often physician-recommended actions to address medication issues were completely timely | 97.1 | 94 |
News Archive
A single compound with dual function - the ability to deliver a diagnostic and therapeutic agent - may one day be used to enhance the diagnosis, imaging and treatment of brain tumors, according to findings from Virginia Commonwealth University and Virginia Tech.
UCB has announced the submission of a Biologics License Application (BLA) to the United States Food and Drug Administration (FDA) for the approval of CIMZIA (certolizumab pegol, CDP870) for the treatment of patients with Crohn's disease.
Neurofeedback is a technique used for the treatment of clinical disorders (like depression, anxiety, chronic pain, ADHD and schizophrenia etc.) and enhancement of brain performance.
Tibotec Pharmaceuticals Ltd. has announced the submission of a New Drug Application to the U.S. Food and Drug Administration (FDA) for TMC125 (etravirine), an investigational non- nucleoside reverse transcriptase inhibitor (NNRTI), being studied for use with other antiretroviral (ARV) agents as a treatment for people infected with HIV- 1.
› Verified 8 days ago
Question Type: | Rating by Patients |
---|---|
Health team gave care in a professional way | |
Health team communicated well with them | |
Health team discussed medicines, pain, and home safety | |
How patients rated overall care from agency |
News Archive
A single compound with dual function - the ability to deliver a diagnostic and therapeutic agent - may one day be used to enhance the diagnosis, imaging and treatment of brain tumors, according to findings from Virginia Commonwealth University and Virginia Tech.
UCB has announced the submission of a Biologics License Application (BLA) to the United States Food and Drug Administration (FDA) for the approval of CIMZIA (certolizumab pegol, CDP870) for the treatment of patients with Crohn's disease.
Neurofeedback is a technique used for the treatment of clinical disorders (like depression, anxiety, chronic pain, ADHD and schizophrenia etc.) and enhancement of brain performance.
Tibotec Pharmaceuticals Ltd. has announced the submission of a New Drug Application to the U.S. Food and Drug Administration (FDA) for TMC125 (etravirine), an investigational non- nucleoside reverse transcriptase inhibitor (NNRTI), being studied for use with other antiretroviral (ARV) agents as a treatment for people infected with HIV- 1.
› Verified 8 days ago
The patient survey data of Companion Home Health is compared against the national average with the color code indicators: Better than National Average Worse than National AverageExperience Measure | Provider | National Avg. |
---|---|---|
Percent of patients who reported that their home health team gave care in a professional way | 89 | 88 |
Percent of patients who reported that their home health team communicated well with them | 88 | 85 |
Percent of patients who reported that their home health team discussed medicines, pain, and home safety with them | 84 | 83 |
Percent of patients who gave their home health agency a rating of 9 or 10 on a scale from 0 (lowest) to 10 (highest) | 89 | 84 |
Percent of patients who reported YES, they would definitely recommend the home health agency to friends and family | 86 | 78 |
News Archive
A single compound with dual function - the ability to deliver a diagnostic and therapeutic agent - may one day be used to enhance the diagnosis, imaging and treatment of brain tumors, according to findings from Virginia Commonwealth University and Virginia Tech.
UCB has announced the submission of a Biologics License Application (BLA) to the United States Food and Drug Administration (FDA) for the approval of CIMZIA (certolizumab pegol, CDP870) for the treatment of patients with Crohn's disease.
Neurofeedback is a technique used for the treatment of clinical disorders (like depression, anxiety, chronic pain, ADHD and schizophrenia etc.) and enhancement of brain performance.
Tibotec Pharmaceuticals Ltd. has announced the submission of a New Drug Application to the U.S. Food and Drug Administration (FDA) for TMC125 (etravirine), an investigational non- nucleoside reverse transcriptase inhibitor (NNRTI), being studied for use with other antiretroviral (ARV) agents as a treatment for people infected with HIV- 1.
› Verified 8 days ago
Companion Home Health Location: 1310 E Oklahoma Avenue, Guthrie, Oklahoma 73044 Ratings: Phone: (405) 293-9000 |